Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 known ✓ | P07900 | 2/20 | 0.41 |
| ▸ | HDAC1 known ✓ | Q13547 | 2/20 | 0.41 |
| ▸ | HDAC3 known ✓ | O15379 | 1/20 | 0.40 |
| ▸ | HDAC2 known ✓ | Q92769 | 1/20 | 0.40 |
| ▸ | HDAC8 known ✓ | Q9BY41 | 1/20 | 0.40 |
| ▸ | HDAC6 known ✓ | Q9UBN7 | 1/20 | 0.40 |
| ▸ | HDAC5 known ✓ | Q9UQL6 | 1/20 | 0.40 |
| ▸ | CACNA1B known ✓ | Q00975 | 1/20 | 0.38 |
| ▸ | MGLL | Q99685 | 11/20 | 0.52 |
| ▸ | FAAH | O00519 | 5/20 | 0.52 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | AOC2 | O75106 | 2/20 | 0.39 |
| ▸ | RXRA | P19793 | 1/20 | 0.38 |
| ▸ | RXRB | P28702 | 1/20 | 0.38 |
| ▸ | RXRG | P48443 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL443354 | 1.00 | MGLL (0.52) | MGLLFAAHDDAH1HSP90AA1NPSR1 | |
| SCHEMBL44044 | 0.99 | MGLL (0.54) | MGLLFAAHDDAH1HSP90AA1NPSR1 | |
| SCHEMBL28390770 | 0.94 | MGLL (0.56) | MGLLFAAHDDAH1HSP90AA1NPSR1 | |
| SCHEMBL13996136 | 0.84 | MGLL (0.57) | MGLLFAAHDDAH1HSP90AA1NPSR1 | |
| SCHEMBL741572 | 0.83 | MGLL (0.59) | MGLLFAAHDDAH1HSP90AA1NPSR1 | |
| SCHEMBL29164209 | 0.82 | MGLL (0.44) | MGLLFAAHDDAH1HSP90AA1NPSR1 | |
| SCHEMBL15811640 | 0.82 | MGLL (0.49) | MGLLFAAHPKMALDH1A1 | |
| Hydrochloric Acid SCHEMBL15953486 | 0.82 | MGLL (0.37) | MGLLFAAHALDH1A1HPGD | |
| Hydrochloric Acid SCHEMBL28737900 | 0.82 | MGLL (0.58) | MGLLFAAHDDAH1HSP90AA1NPSR1 | |
| Water SCHEMBL17644778 | 0.82 | MGLL (0.58) | MGLLFAAHDDAH1HSP90AA1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 334 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110054580-A | The preparation method of 4- (4-N- maleimide phenyl) butyric acid hydrazides hydrochloride | 苏州百灵威超精细材料有限公司 | 2019-07-26 | — | — | CN | claimed |
| EP-2675480-B1 | METHODS OF PREPARATION OF CONJUGATES | IMMUNOGEN INC (US) | 2018-12-26 | — | — | EP | claimed |
| EP-3302531-A1 | IMMUNE TOLERANT AND NON-IMMUNE TOLERANT ELASTIN-LIKE RECOMBINANT PEPTIDES AND METHODS OF USE | University of Utah Research Foundation (US) | 2018-04-11 | — | — | EP | claimed |
| EP-2494075-B1 | TEMPLATED NANOCONJUGATES | UNIV NORTHWESTERN (US) | 2018-04-04 | — | — | EP | claimed |
| CN-107750163-A | Immunological tolerance and nonimmune tolerance elastin-like recombinant peptide and application method | 犹他大学研究基金会 | 2018-03-02 | — | — | CN | claimed |
| WO-2016196249-A1 | IMMUNE TOLERANT AND NON-IMMUNE TOLERANT ELASTIN-LIKE RECOMBINANT PEPTIDES AND METHODS OF USE | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2016-12-08 | — | — | WO | claimed |
| US-9353127-B2 | Methods of preparation of conjugates | IMMUNOGEN, INC. (US) | 2016-05-31 | — | — | US | claimed |
| CN-102666879-B | Templated nanometer conjugate | NORTHWEST UNIVERSITY (US) | 2016-02-24 | — | — | CN | claimed |
| US-8906354-B2 | Loaded latex optical molecular imaging probes containing lipophilic large stokes shift dyes | BRUKER BIOSPIN CORPORATION (US) | 2014-12-09 | — | — | US | claimed |
| US-20130183270-A1 | Orally Bioavailable Lipid-Based Constructs | SDG, INC. (US) | 2013-07-18 | — | — | US | claimed |
| CN-101421323-A | Loaded latex optical molecular imaging probes | CARESTREAM HEALTH INC (US) | 2009-04-29 | — | — | CN | claimed |
| EP-2004713-A2 | LOADED LATEX OPTICAL MOLECULAR IMAGING PROBES | Carestream Health, Inc. (US) | 2008-12-24 | — | — | EP | claimed |
| EP-1549350-B1 | PHARMACEUTICALLY ACTIVE OLIGOSACCHARIDE CONJUGATES | FRESENIUS KABI DE GMBH (DE) | 2008-09-24 | — | — | EP | claimed |
| US-20080181965-A1 | Loaded latex optical molecular imaging probes | QUANTUM MEDICAL HOLDINGS, LLC | 2008-07-31 | — | — | US | claimed |
| WO-2007120579-A2 | LOADED LATEX OPTICAL MOLECULAR IMAGING PROBES | CARESTREAM HEALTH, INC. (US) | 2007-10-25 | — | — | WO | claimed |
| US-20060100163-A1 | Pharmaceutically active oligosaccharide conjugates | FRESENIUS KABI DEUTSCHLAND GMBH (DE) | 2006-05-11 | — | — | US | claimed |
| US-20030148304-A1 | Method for immobilisation | KAROLINSKA INNOVATIONS AB (SE) | 2003-08-07 | — | — | US | claimed |
| US-6573245-B1 | Conjugate including polysaccharide which binds to cell surface of Antigen Presenting Cell, protein or peptide antigen which elicits immunogenic response when covalently attached to polysaccharide, imine-forming compound | GALENICA PHARMACEUTICALS, INC. | 2003-06-03 | — | — | US | claimed |
| EP-1235937-A1 | METHOD FOR IMMOBILISATION | Karolinska Innovations AB (SE) | 2002-09-04 | — | — | EP | claimed |
| WO-2001042501-A1 | METHOD FOR IMMOBILISATION | KAROLINSKA INNOVATIONS AB (SE) | 2001-06-14 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080181965-A1 | Loaded latex optical molecular imaging probes | MLX, LOXL1, EPX | HSP90AA1 4202/4885HDAC1 4181/4885HDAC3 3026/4885 |
| US-20130183270-A1 | Orally Bioavailable Lipid-Based Constructs | FABP2, FABP1, LIPC | HSP90AA1 238/4885HDAC1 4001/4885HDAC3 3495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.